

Regimen Reference Order – ENDO – lenvatinib

ARIA: [ENDO – lenvatinib]

Planned Course: Once daily until disease progression or unacceptable toxicity (1 cycle = 30 days)
Indication for Use: Locally Recurrent or Metastatic, Progressive, Radioactive-Iodine-Refractory Differentiated Thyroid Cancer (DTC)

Proceed with treatment if:

**ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $75 \times 10^9/L$
 Creatinine clearance equal to or greater than 30 mL per minute**

❖ **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – ENDO – lenvatinib

Drug	Dose	CCMB Administration Guideline
lenvatinib	24 mg	Orally once daily (self-administered at home)
lenvatinib (Lenvima®) available dosage strengths: 4 mg and 10 mg capsules Supplied as blister packages in 10 mg, 14 mg, 20 mg and 24 mg daily-dose cartons		
Classification: Cytotoxic, Hazardous		

REQUIRED MONITORING

- Blood pressure:
 - At baseline
 - After 1 week
 - Every 2 weeks for the first 2 months, then monthly thereafter
- Liver function tests:
 - At baseline
 - Every 2 weeks for the first two months, then monthly thereafter

Baseline and each cycle

- CBC, biochemistry as per physician order
- ECG
- Electrolytes
- TSH
- Urinalysis for protein: Where urinalysis is not possible, use dipstick. If lab urinalysis for protein is greater than or equal to 1 g/L or dipstick proteinuria shows 2+ or 3+, notify prescriber.

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
Not Applicable		

INSTRUCTIONS FOR PATIENT

- Ensure patient has been provided with patient information sheet
- Patient should monitor blood pressure at home and record measurements on blood pressure log
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of lenvatinib

ADDITIONAL INFORMATION

- Lenvatinib will be dispensed at CancerCare Manitoba Pharmacy
- Lenvatinib can cause serious side effects such as confusion, seizure, vision changes, weakness, bleeding, chest pain, shortness of breath, severe headache, fainting